
Can We Smell Cancer Before Conventional Tests Can Detect It? Matthew Laskowski, CEO of TOBY
What if we could detect cancer and Alzheimer’s disease using the same biological principle that allows dogs to smell disease?
David Filby is joined by Matthew Laskowski, CEO of TOBY, to explore a new approach to cancer detection, multi-cancer early detection (MCED) and Alzheimer’s diagnostics.
Matthew explains how TOBY combines mass spectrometry with machine learning — replacing, as he puts it, “a dog’s nose with mass spec and a dog’s brain with machine learning.” Rather than searching for a single “silver bullet” biomarker, TOBY looks at patterns across multiple weaker signals that can become powerful when analysed together.
Matthew also discusses TOBY’s three FDA Breakthrough Device designations across bladder cancer screening, MCED and Alzheimer’s diagnostics, its prostate cancer validation work, and where he believes the technology could have the greatest clinical impact — including improving early-stage detection and potentially reducing reliance on invasive biopsies.
The conversation also explores TOBY’s path towards a laboratory-developed test (LDT), the role of CLIA laboratories, partnerships and reimbursement, and how Matthew’s background in software, AI and data science has shaped a different approach to building and commercialising a diagnostics company.
Key takeaways:
🔹 How volatile organic compounds (VOCs) could provide a new source of diagnostic signals for cancer and other diseases
🔹 Why TOBY combines mass spectrometry and machine learning to analyse patterns across multiple biomarkers
🔹 Why aggregating many weaker signals could be more powerful than searching for a single “silver bullet” biomarker
🔹 How TOBY is approaching multi-cancer early detection, Alzheimer’s diagnostics and the challenge of detecting disease at earlier stages
🔹 Why reducing reliance on invasive biopsies, developing LDTs and building commercial partnerships are central to TOBY’s strategy
Chapters:
00:00 Introduction
05:48 How TOBY uses VOCs to “smell” disease
07:52 Why multiple weak signals can create a stronger diagnostic signal
09:56 Three FDA Breakthrough Device designations: bladder cancer, MCED and Alzheimer’s
13:43 Early cancer detection and reducing reliance on biopsies
15:43 Validation and the path towards an LDT
19:56 Rethinking diagnostics commercialisation and reimbursement
25:21 Future milestones and commercial traction
26:01 Why Matthew is optimistic about the future of diagnostics
Guest: Matthew Laskowski
CEO of TOBY
LinkedIn: https://www.linkedin.com/in/matthew-laskowski-785495a1/
Learn more about TOBY here: https://www.toby.health/
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/
🔔 Subscribe to Diagnosing Dx for weekly conversations exploring how novel science is translated, scaled and brought into clinical practice across diagnostics, omics and precision medicine.
More episodes from "Diagnosing Dx"



Don't miss an episode of “Diagnosing Dx” and subscribe to it in the GetPodcast app.








